Financial Performance - The company's operating revenue for 2021 was ¥8,108,586,464.73, representing a 3.04% increase compared to ¥7,869,425,144.32 in 2020[20] - The net profit attributable to shareholders decreased by 34.28% to ¥1,155,709,191.19 from ¥1,758,477,255.29 in the previous year[20] - The net profit after deducting non-recurring gains and losses dropped significantly by 96.43% to ¥62,125,153.70, down from ¥1,741,826,559.80 in 2020[20] - The net cash flow from operating activities was ¥2,245,545,736.13, a decrease of 38.84% compared to ¥3,671,535,996.49 in 2020[20] - Basic earnings per share fell by 37.91% to ¥1.13 from ¥1.82 in the previous year[20] - Diluted earnings per share also decreased by 36.42% to ¥1.10 from ¥1.73 in 2020[20] - The weighted average return on equity for 2021 was 10.32%, a decrease from 19.31% in 2020[21] - Total assets at the end of 2021 were approximately ¥16.91 billion, a decrease of 0.71% compared to the end of 2020[21] - Net assets attributable to shareholders increased by 7.32% year-over-year, reaching approximately ¥10.54 billion at the end of 2021[21] Business Operations and Strategy - The main business has shifted to include health protection, medical devices, and nursing services[18] - The company plans to distribute a cash dividend of ¥1.00 per 10 shares (including tax) to all shareholders[4] - The company is under the continuous supervision of Morgan Stanley Securities and CITIC Securities as financial advisors[19] - The company has not made any adjustments or restatements to previous years' accounting data[20] - The company has launched new product lines, including family emergency kits and training emergency kits, which received positive feedback at the CMEF Shanghai exhibition[38] - The company is enhancing its production efficiency and sustainability by implementing smart manufacturing technologies and pursuing carbon neutrality goals[42] - The company is actively developing new products, including a drug-coated balloon for small vessel lesions, expected to be the only product of its kind in the domestic market[69] - The company is expanding its product lines in the cardiovascular sector, including structural heart disease and heart failure, to enhance its competitive edge[147] Market and Industry Insights - The Chinese medical device market is projected to reach ¥833.6 billion in 2021, growing at a compound annual growth rate of 19.8% from 2016 to 2019[33] - The global demand for disposable protective gloves is expected to grow at a compound annual growth rate of 15.9%, reaching approximately 12.85 trillion units by 2025[31] - The TAVR market in China grew from CNY 41 million in 2017 to CNY 556 million in 2020, with a compound annual growth rate (CAGR) of 138.1%[36] - The global market for medical emergency kits reached USD 495 million in 2019 and is expected to grow to USD 744 million by 2026, with a CAGR of 5.90%[37] - The total market size of China's health industry is projected to grow from 8.1 trillion RMB in 2019 to approximately 13.4 trillion RMB by 2024[68] Research and Development - The company invested 518.21 million yuan in R&D during the reporting period, with over 550 patents obtained[61] - The total R&D investment for 2021 was approximately ¥518.21 million, representing a 49.47% increase from ¥346.69 million in 2020[99] - R&D investment accounted for 6.39% of total revenue in 2021, up from 4.41% in 2020, indicating a 1.98% increase[99] - The company is continuously increasing investment in R&D and clinical trials for heart valve and coronary products, despite the current limited market performance[58] Corporate Governance - The company emphasizes investor relations management, actively engaging with investors and ensuring their right to information[167] - The governance structure of the company complies with the requirements set by the China Securities Regulatory Commission[169] - The company maintains complete independence from its controlling shareholders in terms of business operations, personnel, assets, organization, and finance[170] - The company has established a fully independent financial accounting department with dedicated financial personnel and a standardized financial management system[171] Financial Management and Investments - The total amount of funds raised by the company reached 314,404 million CNY, with 38,924.57 million CNY utilized during the reporting period[126] - The company confirmed an investment income of 684.1 thousand CNY from financial derivatives, with an initial investment amount of 456,656.8 thousand CNY[124] - The company has committed to using simple, controllable, and liquid financial derivatives for hedging purposes to prevent and mitigate risks[124] - The company has established strict approval procedures for fund allocation and usage to enhance financial management[124] Future Outlook - The company plans to invest several hundred million CNY to establish Wuhan Bikaier as the leading global enterprise in medical emergency kits[39] - The company plans to launch new products in the structural heart disease sector, with clinical trials for the second-generation aortic valve planned for 2022[46] - The company aims to create a sustainable development model by establishing a decentralized organization and a multi-level partnership mechanism[76] - The company plans to achieve an operating revenue target of 6.5 billion yuan for 2022, with the realization dependent on market conditions and operational efforts[145]

证券代码：002382 证券简称：蓝帆医疗 公告编号：2021-103 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 关于参加山东辖区上市公司2021年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的互动交流，蓝帆医疗股份有限公司（以下简称"公 司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司联合举办 的 "山东辖区上市公司 2021 年度投资者网上集体接待日"活动，现将有关事项公告 如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网上平台 采取网络远程的方式举行，投资者可以登陆"全景•路演天下"网站（http://rs.p5w.net） 参与公司本次投资者集体接待日活动，活动时间为 2021 年 11 月 16 日（星期二）下午 14:00-16:00。 届时公司董事、副总裁兼首席财务官孙传志先生、董事、副总裁、首席资本官兼 董事会秘书钟舒乔先生和证券事务代表赵敏女士将通过网络在线形式与投资者进行沟 通交流。欢迎广大投资者积极参与。 特此 ...

蓝帆医疗股份有限公司 2021 年第三季度报告 证券代码：002382 证券简称：蓝帆医疗 公告编号：2021-096 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 2021年第三季度报告 本公司及董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3、第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------- ...

蓝帆医疗股份有限公司 2021 年半年度报告全文 1 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） | --- | --- | --- | |-------|----------------------|-------| | | | | | | | | | | | | | | 二〇二一年半年度报告 | | | | （未经审计） | | | | 股票代码： 002382 | | 二〇二一年八月 蓝帆医疗股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本半年度报告中详细描述了公司面临的风险，敬请投资者予以关 注，详见本报告"管理层讨论与分析"等章节中关于公司面临风险和应对措施的 ...

蓝帆医疗股份有限公司 2021 年第一季度报告正文 1 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 二〇二一年第一季度报告 | | | | | | | （未经审计） | | | | | | | 股票代码： | | 二〇二一年四月 蓝帆医疗股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员 ...

Financial Performance - The company reported a cash dividend of 4 RMB per 10 shares (including tax) for all shareholders, with no bonus shares issued[6]. - The company’s revenue for the reporting period was not specified in the provided content, but it is essential to refer to the financial report for detailed figures[20]. - The company's operating revenue for 2020 was ¥7,869,425,144.32, representing a 126.42% increase compared to 2019[23]. - The net profit attributable to shareholders for 2020 was ¥1,758,477,255.29, a significant increase of 258.66% from the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,741,826,559.80, up 268.23% year-over-year[23]. - The net cash flow from operating activities reached ¥3,671,535,996.49, marking a 369.03% increase compared to 2019[23]. - The basic earnings per share for 2020 was ¥1.82, a 256.86% increase from ¥0.51 in 2019[23]. - The total assets at the end of 2020 were ¥17,034,777,959.42, reflecting a growth of 28.48% from the previous year[26]. - The net assets attributable to shareholders at the end of 2020 were ¥9,817,206,393.25, an increase of 16.42% compared to 2019[26]. - The company recorded a profit before tax of ¥201,838.82 million, reflecting a year-on-year growth of 250.23%[75]. - The company achieved a revenue of ¥786,942.51 million in 2020, representing a year-on-year growth of 126.42%[75]. - The net profit attributable to shareholders reached ¥175,847.73 million, with a year-on-year increase of 258.66%[75]. Business Strategy and Expansion - The main business has shifted from health protection to include medical devices and nursing services[21]. - The company has been focusing on expanding its health protection, medical device, and nursing service sectors[21]. - The company aims to enhance its product pipeline through internal R&D and self-built initiatives over the next five years[37]. - The company is focusing on expanding its presence in the global medical device market, targeting a position among the top 50 companies in the industry[37]. - The company plans to invest 800 million yuan to develop Wuhan Bikaier into a leading global medical emergency kit enterprise, expanding its product range to include various medical and daily care products[43]. - The company plans to implement a brand marketing strategy over the next 3-5 years, aiming for dual growth in profits and market value[66]. - The company is actively pursuing market expansion through the introduction of new products and technologies in the medical device sector[114]. - The company is focusing on the development of new technologies and products in the medical and protective glove industry[200]. Product Development and Innovation - The company has segmented its business into three divisions: Protective Products, Cardiovascular Products, and Nursing Products, each focusing on specific medical device markets[38]. - The cardiovascular division's subsidiary, Jive Medical, is one of the top three players in the domestic cardiac stent market, with proprietary drug Biolimus A9TM and the first drug-eluting stent BioFreedomTM, significantly reducing post-operative antiplatelet medication duration from 1 year to 1 month[41]. - The company has developed a leading product portfolio in cardiovascular devices, including the first biodegradable polymer drug-eluting stent and the first drug-coated balloon[58]. - The company is expanding its product offerings in the cardiovascular field, including new balloon catheters and stents, with several products in clinical trials[129]. - The company is expanding its product offerings in the health protection field, focusing on medical gloves and other protective equipment[114]. - The company launched a new modified polymer NTH glove in response to the pandemic, which offers better performance than standard PVC gloves at a lower price than nitrile gloves[94]. - The company has obtained certifications for various medical protective equipment, including masks and gloves, in multiple regions[127]. Market Performance and Demand - The global demand for medical and protective products surged due to the COVID-19 pandemic, leading to significant increases in sales orders and prices, positively impacting the company's performance[44]. - The company expects strong global demand for protective products to continue for a considerable period[51]. - The sales volume of health protection products increased by 41.00% year-on-year, reaching 2.44 billion units in 2020[138]. - The sales volume of cardiovascular products decreased by 36.00% year-on-year, totaling 496,000 units[138]. - The company’s sales of protective products, including masks and gloves, saw significant growth due to the pandemic, enhancing brand influence in international markets[102]. - The company’s heart intervention device sales and implant volumes experienced a decline due to the pandemic, but a rebound is expected post-pandemic[105]. Acquisitions and Investments - The company’s controlling shareholder changed from Blue Sail Group to Blue Sail Investment[21]. - The acquisition of NVT AG, a leading TAVR production company, positions the company in a high-growth market for structural heart disease intervention devices[42]. - The company completed the acquisition of Wuhan Bikaier Rescue Supplies Co., Ltd. with a 100% equity stake on July 25, 2020[184]. - The company invested 172 million RMB in Nanjing Wofuman Medical Technology, acquiring a 16.38% stake to support the development of domestic OCT products[60]. - The company raised a total of 314.404 million CNY through convertible bonds to fund acquisitions and expand production capacity for health protection products[108]. Research and Development - The company has established eight global R&D and clinical registration platforms, employing over 1,000 R&D personnel, ensuring a 24-hour global R&D system[61]. - The company has over 410 patents, maintaining a leading position in its industry[61]. - The number of R&D personnel increased by 108.64% to 1,135, and R&D investment amounted to ¥346,689,295.87, which is 4.41% of operating revenue[160]. - The company is focused on enhancing its research and development capabilities to innovate new medical products[114]. Regulatory Compliance and Certifications - The company has obtained various certifications for its medical gloves, including FDA registration in the United States and CE certification in the European Union[119]. - The total number of medical device registration certificates reflects the company's commitment to compliance and quality assurance in its product offerings[114]. - The number of medical device registration certificates at the end of the reporting period reached 688, up from 557 at the end of last year, representing an increase of 23.5%[114]. - During the reporting period, 156 new medical device registration certificates were added, while 25 certificates became invalid[114]. Operational Efficiency - The company has established a comprehensive medical device business platform that integrates low, medium, and high-value consumables[54]. - The company has established online flagship stores on major e-commerce platforms, steadily increasing sales through social media collaborations[64]. - The company has established 9 overseas warehouses in 8 countries and regions to enhance supply chain efficiency and support global demand for medical protective products[102]. - The company has incorporated several subsidiaries into its consolidation scope in 2020, enhancing its operational capabilities[142].

蓝帆医疗股份有限公司 2020 年第三季度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 二〇二〇年第三季度报告 | | | | | | | （未经审计） | | | | | | | 股票代码： 002382 | | 二〇二〇年十月 1 蓝帆医疗股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明： ...

证券代码：002382 证券简称：蓝帆医疗 公告编号：2020-110 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 关于参加山东辖区上市公司2020年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，构建和谐投资者关系，蓝帆医疗股份有 限公司（以下简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景 网络有限公司联合举办的 "山东辖区上市公司 2020 年度投资者网上集体接待日"活 动，现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上平台举 行，投资者可以登陆"全景•路演天下"网站（http://rs.p5w.net）参与公司本次投资者 集体接待日活动，活动时间为 2020 年 9 月 29 日（星期二）下午 15:00-16:55。 届时公司董事、副总裁、首席资本官兼董事会秘书钟舒乔先生和证券事务代表赵 敏女士将通过网络在线形式与投资者就公司治理、发展战略和经营状况等投资者关注 的问题进行沟通交流。欢迎广大投资者积极参 ...

蓝帆医疗股份有限公司 2020 年半年度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇二〇年半年度报告 （未经审计） 股票代码：002382 二〇二〇年八月 1 蓝帆医疗股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本半年度报告中详细描述了公司面临的风险，敬请投资者予以关 注，详见本年度报告"经营情况讨论与分析"等章节中关于公司面临风险的描述。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 5 | | ...

蓝帆医疗股份有限公司 2020 年第一季度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------|------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 二〇二〇年第一季度报告 | | | | | | | | | （未经审计） | | | | | | | | | 股票代码： 002382 | | 二〇二〇年四月 1 蓝帆医疗股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 除下列董事外，其他董事 ...